G. Steven Burrill
An introduction to Burrill Venture Capital
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech takes a beating in market meltdown October 01, 2008 | Press Release
Biotech outperforms market in May June 02, 2008 | Press Release
Biotech Treads Water in April May 01, 2008 | Press Release
See all NewsVenture Capital
Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey’s broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company’s patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system – a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company’s lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease.
